Sector News

Pfizer rejigs executive roster to put Albert Bourla at Read's right hand

November 13, 2017
Life sciences

Pfizer now has a chief operating officer and, potentially, a successor to CEO Ian Read. It’s Albert Bourla, who’s headed up the company’s Innovative Health unit since early 2016.

Adding a COO to the executive roster will allow Read to “spend more time focusing on the company’s long-term strategic direction, ensuring continued R&D productivity and engaging with government policy and industry leaders on key issues facing the future of the healthcare industry,” the CEO said in the statement.

It also sets up Bourla at Read’s right hand, a spot that’s auspicious for his future at the company, as the Wall Street Journal noted. Read is 64, and though he’s not ready to make an exit, he did want to set up a plan for his succession when the time comes, the newspaper reported, citing an anonymous source.

Bourla will move into the newly created slot on Jan. 1, the company said in a Monday statement. He’ll oversee R&D, sales and strategy across the company, Pfizer said. His promotion will trigger other management switches; John Young, who’s been running Pfizer’s Established Products unit, will move into Bourla’s current job, and Angela Hwang, who heads up the company’s inflammation and immunology business, will take over at Established Products.

In announcing the move, Pfizer emphasized Bourla’s recent success at driving growth in the Innovative Health business, with 9% revenue growth so far this year. Cancer med Ibrance, which Bourla handled in his previous role as president of vaccines, oncology and consumer health, has been among the company’s most successful recent launches.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.